

Ascendiant Capital Markets LLC serves as Sole Sales Agent on \$20,000,000 At-The-Market (ATM) Offering for ENDRA Life Sciences, Inc.

JUPITER, Florida – June 21, 2021 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the closing of a \$20,000,000 At-The-Market (ATM) Offering for ENDRA Life Sciences, Inc. (Nasdaq: NDRA) of Ann Arbor, Michigan.

Ascendiant is serving as the sole Sales Agent on the transaction.

ENDRA intends to use the net proceeds from this offering for general corporate purposes and working capital.

About ENDRA Life Sciences, Inc.

ENDRA Life Sciences Inc. (Nasdaq: NDRA) is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the over one million ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 561.427.1727 or bwilhite@ascendiant.com

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.